Alcon (XSWX:ALCE) Stock Based Compensation: CHF134 Mil (TTM As of Mar. 2026)


XSWX:ALCE Alcon Inc XSWX:ALCE
53 GF Score
Price CHF55.60
GF Value CHF73.46
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alcon Stock Based Compensation?

Alcon XSWX:ALCE +3.65% 53 Stock Based Compensation is CHF134 Mil as of Mar. 2026. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Alcon's Stock Based Compensation for the three months ended in Mar. 2026 was CHF35 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was CHF134 Mil.

Alcon Stock Based Compensation Related Terms

Alcon Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Alcon's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alcon Stock Based Compensation Chart

Alcon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.10 130.42 124.53 133.74 129.10

Alcon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.46 30.90 32.64 35.06 35.43
XSWX:ALCE
53GF Score
Alcon Inc XSWX:ALCE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alcon Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF134 Mil.

What does a Stock Based Compensation of CHF134 Mil mean?
Alcon (XSWX:ALCE) has a Stock Based Compensation of CHF134 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alcon and its competitors.
Is Alcon's Stock Based Compensation too high?
Alcon's current Stock Based Compensation is CHF134 Mil. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Stock Based Compensation compare to ISRG and BDX?
Alcon's Stock Based Compensation of CHF134 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alcon and its competitors. Alcon's current Stock Based Compensation is CHF134 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current Stock Based Compensation is CHF134 Mil. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current Stock Based Compensation is CHF134 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alcon (XSWX:ALCE) Overvalued in 2026?

Based on GuruFocus' analysis, Alcon stock appears to be undervalued. The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46. GuruFocus considers Alcon to be Modestly Undervalued.

Key valuation signals for XSWX:ALCE:

  • Stock Based Compensation: CHF134 Mil
  • GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alcon Business Description

Address Chemin de Blandonnet 8, Vernier, Geneva, CHE, 1214
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score

Get the complete analysis for XSWX:ALCE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF55.60
Price
CHF73.46
GF Value